MX2013000361A - Derivados de bisaril (tio)morfolina como moduladores s1p. - Google Patents

Derivados de bisaril (tio)morfolina como moduladores s1p.

Info

Publication number
MX2013000361A
MX2013000361A MX2013000361A MX2013000361A MX2013000361A MX 2013000361 A MX2013000361 A MX 2013000361A MX 2013000361 A MX2013000361 A MX 2013000361A MX 2013000361 A MX2013000361 A MX 2013000361A MX 2013000361 A MX2013000361 A MX 2013000361A
Authority
MX
Mexico
Prior art keywords
alkyl
optionally substituted
fluoro atoms
halogen
substituted
Prior art date
Application number
MX2013000361A
Other languages
English (en)
Other versions
MX338605B (es
Inventor
Bakker Wouter I Iwema
Raymond Bronger
Original Assignee
Abbvie Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Bv filed Critical Abbvie Bv
Publication of MX2013000361A publication Critical patent/MX2013000361A/es
Publication of MX338605B publication Critical patent/MX338605B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

La presente invención se relaciona con derivados de bisaril (tio) morfolina de la fórmula (I) (Ver Formula) en donde R1 es un sustituyente arilo se selecciona de fenilo, piridilo, pirimidinilo, bifenilo y naftilo, cada uno opcionalmente sustituido con uno o más sustituyentes seleccionados independientemente de halógeno, alquilo (C 1-6) opcionalmente sustituido con uno o más átomos de flúor, alcoxi (C 1-4) opcionalmente sustituido con uno o más átomos de flúor, amino, dialquilamino (C 1-4), -S02-alquilo (C 1-4), -CO-alquilo (C 1-4), -CO-O-alquilo (C 1-4) y -NHCO-alquilo (C 1-4), o sustituido con fenoxi, bencilo, benciloxi, feniletilo o morfolinilo, cada uno opcionalmente sustituido con alquilo (C 1-4), y grupo bicíclico (C 8-10), heterociclo bicíclico, cada uno opcionalmente sustituido con alquilo (C 1-4) opcionalmente sustituido con uno o más átomos de flúor o oxo; A se selecciona de -CO-, -NH-, -O-, -S-, -SO- o -SO2-; la estructura del anillo B contiene opcionalmente un átomo de nitrógeno; R2 es H, alquilo (C 1-4) opcionalmente sustituido con uno o más átomos de flúor, alcoxi (C 1-4) opcionalmente sustituido con uno o más átomos de flúor, o halógeno; y R3 es alquileno (C 1-4)-R6 en donde el grupo alquileno se puede sustituir con (CH2)2 para formar un grupo funcional ciclopropilo o con uno o más átomos de halógeno, o R3 es cicloalquileno (C 3-6)-R5 o -CO-CH2-R6, en donde R6 es - OH, -P03H2, -0P03H2, -COOH, -COOalquilo (C 1-4) o tetrazol -5- ilo; R4 es H o alquilo (C 1-4); R5 es uno o más sustituyentes seleccionados independientemente de H, alquilo (C 1-4) o oxo; W es -O-, -S-, -SO- o -SO2-; o una sal farmacéuticamente aceptable, un solvato o hidrato del mismo, con la condición de que el derivado de la fórmula (I) no es 2-[4-(4-cborofenoxi) -2- cloro -fenil]-4-morfolinaetanol; los compuestos de la invención tienen afinidad con los receptores S1P y se pueden utilizar en el tratamiento, alivio o prevención de enfermedades y afecciones mediadas por el receptor S1P.
MX2013000361A 2010-07-09 2011-07-08 Derivados de bisaril (tio)morfolina como moduladores s1p. MX338605B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36278510P 2010-07-09 2010-07-09
EP10169108 2010-07-09
US201161452977P 2011-03-15 2011-03-15
EP11158269 2011-03-15
PCT/EP2011/061590 WO2012004375A1 (en) 2010-07-09 2011-07-08 Bisaryl (thio)morpholine derivatives as s1p modulators

Publications (2)

Publication Number Publication Date
MX2013000361A true MX2013000361A (es) 2013-04-29
MX338605B MX338605B (es) 2016-04-22

Family

ID=44323383

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000361A MX338605B (es) 2010-07-09 2011-07-08 Derivados de bisaril (tio)morfolina como moduladores s1p.

Country Status (13)

Country Link
US (3) US9029371B2 (es)
EP (1) EP2590954B1 (es)
JP (1) JP5841593B2 (es)
CN (1) CN103080096B (es)
AR (1) AR082137A1 (es)
CA (1) CA2804329C (es)
DK (1) DK2590954T3 (es)
ES (1) ES2570744T3 (es)
MX (1) MX338605B (es)
PL (1) PL2590954T3 (es)
TW (1) TW201206893A (es)
UY (1) UY33495A (es)
WO (1) WO2012004375A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI522361B (zh) * 2010-07-09 2016-02-21 艾伯維公司 作為s1p調節劑的稠合雜環衍生物
TW201643169A (zh) 2010-07-09 2016-12-16 艾伯維股份有限公司 作為s1p調節劑的螺-哌啶衍生物
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9181230B2 (en) 2012-01-12 2015-11-10 Hoffmann-La Roche Inc. Morpholine compounds and uses thereof
CN102670617B (zh) * 2012-04-13 2013-03-20 湖南大学 布洛芬2-（2-芳基吗啉-4-基）乙酯作为制备抗抑郁药物的应用
BR112022008113A2 (pt) 2019-10-31 2022-07-19 Escape Bio Inc Formas sólidas de um modulador de receptor s1p

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1069387A1 (ru) 1982-07-01 1985-11-30 Институт физико-органической химии и углехимии АН УССР Дигидрохлорид 5-/ @ -( @ -анизил)- @ -оксиэтил/ 2-(3,4-диметоксифенил)-1-метил-4,5,6,7-тетрагидроимидазо(4,5- @ )пиридина,обладающий спазмолитическим действием
GB2228432A (en) 1989-01-13 1990-08-29 Grayston Central Services Multi-role machine for heating and coating pipe welds.
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
JP2681589B2 (ja) 1992-12-28 1997-11-26 日揮株式会社 配管溶接継手の熱処理方法
JPH072848A (ja) 1993-04-23 1995-01-06 Sankyo Co Ltd モルホリンおよびチオモルホリン誘導体
GB9522845D0 (en) 1995-11-08 1996-01-10 Smithkline Beecham Plc Novel compounds
JP3822680B2 (ja) 1996-08-30 2006-09-20 新日本製鐵株式会社 誘導加熱された接合部の冷却方法および冷却装置
JP4518587B2 (ja) * 1998-03-09 2010-08-04 興和創薬株式会社 ２−フェニルモルホリン誘導体
MXPA02010325A (es) 2000-04-21 2003-04-25 Shionogi & Co Derivados de oxadiazol los cuales tienen efectos anticancer.
FR2822727A1 (fr) 2001-04-03 2002-10-04 Gesal Ind Procede d'application d'un revetement resistant aux hautes temperatures, dispositif pour la mise en oeuvre de ce procede et objet pourvu dudit revetement
JP3649223B2 (ja) 2003-01-08 2005-05-18 株式会社日立製作所 配管系の熱処理方法および熱処理装置
BRPI0411124A (pt) * 2003-06-12 2006-07-18 Btg Int Ltd hidroxilamina cìclica como compostos psicoativos
EP1663188B1 (en) 2003-09-12 2016-08-10 Newron Sweden AB Treatment of disorders of the nervous system
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
GEP20084550B (en) 2004-04-30 2008-11-25 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders
WO2006047195A2 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
JP4491334B2 (ja) 2004-12-01 2010-06-30 日立Ｇｅニュークリア・エナジー株式会社 配管の熱処理方法および装置
JP4599250B2 (ja) 2005-08-10 2010-12-15 株式会社東芝 高周波誘導加熱時外面温度制御方法および当該制御装置
JP2007063642A (ja) 2005-09-01 2007-03-15 Hitachi Ltd 残留応力改善方法と高周波誘導加熱用コイル
ES2462240T3 (es) 2006-02-28 2014-05-22 Dart Neuroscience (Cayman) Ltd Piperazinas terapéuticas como inhibidores de PDE4
US20100009969A1 (en) 2006-07-27 2010-01-14 Ucb Pharma, S.A. Fused Oxazoles & Thiazoles As Histamine H3- Receptor Ligands
CN101511783A (zh) 2006-09-08 2009-08-19 诺瓦提斯公司 用于治疗淋巴细胞相互作用介导的疾病的n-联芳(杂)芳基磺酰胺衍生物
TW200838497A (en) 2006-12-21 2008-10-01 Abbott Lab Sphingosine-1-phosphate receptor agonist and antagonist compounds
AU2008209672B2 (en) * 2007-02-02 2011-02-10 Novartis Ag Chromene S1P1 receptor antagonist
EP2121648A2 (en) 2007-03-21 2009-11-25 EPIX Pharmaceuticals, Inc. S1p receptor modulating compounds and use thereof
EA200901389A1 (ru) 2007-04-23 2010-04-30 Новартис Аг Производные фталазина и изохинолина с модулирующим действием на s1p рецепторы
WO2009084501A1 (ja) 2007-12-27 2009-07-09 Asahi Kasei Pharma Corporation スルタム誘導体
MX2010008382A (es) 2008-01-30 2010-11-25 Cephalon Inc Derivados de piperidina espirociclicos substituidos, como ligandos de receptores de histamina-3 (h3).
CA2712897A1 (en) 2008-01-30 2009-08-06 Pharmacopeia, Inc. Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
US20090321144A1 (en) 2008-06-30 2009-12-31 Wyble Kevin J Protecting an element from excessive surface wear by localized hardening
UY32858A (es) * 2009-08-31 2011-03-31 Abbott Healthcare Products Bv Derivados de (tio)morfolina como moduladores de sip
AR080133A1 (es) 2010-02-04 2012-03-14 Esteve Labor Dr Clorhidrato de 4-(-2-((5-metil-1-(2-naftalenil)-1h-pirazol-3-il)oxi)etil)morfolina y formas cristalinas del mismo
CN101812058B (zh) 2010-04-13 2012-03-21 湖南大学 吲哚美辛2-芳基吗啉乙酯及其制备方法与应用

Also Published As

Publication number Publication date
PL2590954T3 (pl) 2016-09-30
EP2590954B1 (en) 2016-04-13
US9227960B2 (en) 2016-01-05
CN103080096A (zh) 2013-05-01
CA2804329C (en) 2019-05-14
JP2013531003A (ja) 2013-08-01
CA2804329A1 (en) 2012-01-12
US20160151376A1 (en) 2016-06-02
CN103080096B (zh) 2015-12-09
ES2570744T3 (es) 2016-05-20
US9029371B2 (en) 2015-05-12
JP5841593B2 (ja) 2016-01-13
UY33495A (es) 2012-01-31
DK2590954T3 (en) 2016-05-02
US20150191457A1 (en) 2015-07-09
TW201206893A (en) 2012-02-16
US9662337B2 (en) 2017-05-30
MX338605B (es) 2016-04-22
WO2012004375A1 (en) 2012-01-12
AR082137A1 (es) 2012-11-14
US20130203745A1 (en) 2013-08-08
EP2590954A1 (en) 2013-05-15

Similar Documents

Publication Publication Date Title
NZ598300A (en) (thio)morpholine derivatives as s1p modulators
MX2013000361A (es) Derivados de bisaril (tio)morfolina como moduladores s1p.
JP2017502940A5 (es)
PH12020551305A1 (en) Pharmaceutical Compounds
MX2022001908A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina.
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
JP2016513661A5 (es)
EA201992126A1 (ru) Ингибиторы jak, содержащие 4-членный гетероциклический амид
MX2016009403A (es) Compuestos heterociclicos.
JP2016536364A5 (es)
JP2016516699A5 (es)
MX2016007346A (es) Derivados de dihidropiridinona y dihidropiridazinona utiles como inhibidores de bromodominio.
NZ613219A (en) Heterocyclic containing entities, compositions and methods
RS54260B1 (en) AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT
RU2013154412A (ru) Аминопиримидины в качестве ингибиторов syc
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.
JP2015514808A5 (es)
RU2016134751A (ru) Соединения
MA38323A1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
NZ630721A (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
AR073551A1 (es) Pirimidinas macrociclicas como inhibidores de proteina cinasa
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
JP2017504635A5 (es)
RU2012125971A (ru) Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
PH12018500294A1 (en) 5-(n-benzyl tetrahydroisoquinolin-6-yl) pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Legal Events

Date Code Title Description
FG Grant or registration